As part of this year's Hradec Pneumological Days (HPD 2022), the head of the Pulmonary Clinic at Charles University Faculty of Medicine and University Hospital Hradec Králové, Assoc. Prof. Vladimír Koblížek, M.D., Ph.D., reflected on the different rates of prescription of mucoactive drugs to COPD patients in various European countries. According to him, it is clear that in real practice, this treatment works. So what is the reason for its varying prescription across the old continent?
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
